Literature DB >> 19465827

The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy.

Lucia Palmisano, Clementina M Galluzzo, Marina Giuliano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19465827     DOI： 10.1097/QAI.0b013e3181a5b247

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  3 in total

1.  Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.

Authors:  Andrea De Vito; Annarita Botta; Marco Berruti; Valeria Castelli; Vincenzo Lai; Chiara Cassol; Alessandro Lanari; Giulia Stella; Adrian Shallvari; Antonia Bezenchek; Antonio Di Biagio
Journal:  J Pers Med       Date:  2022-01-31

2.  Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

Authors:  Sikhulile Moyo; Simani Gaseitsiwe; Melissa Zahralban-Steele; Dorcas Maruapula; Tapiwa Nkhisang; Baitshepi Mokaleng; Terence Mohammed; Tsotlhe R Ditlhako; Ontlametse T Bareng; Thatayaone P Mokgethi; Erik van Widenfelt; Molly Pretorius-Holme; Madisa O Mine; Elliot Raizes; Etienne Kadima Yankinda; Kathleen E Wirth; Tendani Gaolathe; Joseph M Makhema; Shahin Lockman; Max Essex; Vlad Novitsky
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

3.  High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.

Authors:  Paul E Sax; Kristen Andreatta; Jean-Michel Molina; Eric S Daar; Debbie Hagins; Rima Acosta; Michelle L D'Antoni; Silvia Chang; Ross Martin; Hui Liu; Christiana Blair; Ian McNicholl; Joel Gallant; Sean E Collins; Hal Martin; Kirsten L White
Journal:  AIDS       Date:  2022-04-23       Impact factor: 4.632
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.